The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) on behalf of the National Human Genome Research Institute, (NHGRI), intends to negotiate and award a purchase order on a noncompetitive sole source basis to Illumina, Inc.

The following Reagents for this Requirement:

1. TruSeq Custom Oligo Set, Catalog Number: FC-121-0200, Units: 1, 152 Samples.
2. Shipping and Insurance.

BACKGROUND:

The National Institutes of Health (NIH) is the nation's leading medical research agency and the primary Federal agency conducting and supporting medical discoveries that improve people's health and save lives. The National Human Genome Research Institute (NHGRI), NIH Intramural Sequencing Center (NISC) is a centralized research facility for performing high-throughput, large-scale DNA sequencing and sequence analysis. The NIH Intramural Sequencing Center (NISC), established in 1997, is a multi-disciplinary genomics facility that emphasizes the generation and analysis of DNA sequence. In addition to providing investigators at the NIH access to large-scale DNA sequencing, NISC plays a major role in several efforts related to the Human Genome Project including a Comparative Vertebrate Sequencing Initiative, the ENCODE Project, and the Mammalian Gene Collection Program. NISC is also an active participant in the International Sequencing Consortium.

PERIOD OF PERFORMANCE:

Delivery will be within 6-8 weeks of receiving approved purchase order.

PROJECT DESCRIPTION

While it is currently feasible to sequence an entire genome it is quite expensive and unwieldy. When an investigator wishes to study only selected genes or genomic regions it is more cost-effective and efficient to perform targeted sequencing. The goal is to discover as many variants linked to fanco anemia as possible. The investigator has a collection of many hundreds of samples, so the system must be compatible with large sample numbers. TruSeq Custom Enrichment is an in-solution capture assay for targeting and enriching user-selected human genomic regions of ~500 kb - 25 Mb of cumulative DNA per sample for fully-customized re-sequencing. The assay is ideal for targeting specific genomic content, such as variant validation, examination of specific genes in pathways, or as a follow-up to GWAS.

REGULATORY AUTHORITY

This acquisition is conducted under the authority of 41 U.S.C. 253(c) as set forth under FAR Part 13.106-1 (b) (1), Soliciting from a single source not exceeding the simplified acquisition threshold, and is exempt from the requirements of FAR Part 6, Competition Requirements.

ADDITIONAL INFORMATION

Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology and the Small Business Size Standard is 500 Employees. The resultant Contract will include all applicable provisions and clauses in effect through the Federal Acquisition Circular (FAC) 05-65 (January 29, 2013).

The determination by the Government to award a purchase order on a sole source on competitive basis for TruSeq Custom Oligo Set to Illumina, Inc. is based upon the responses to the sources sought synopsis published in the FedBizOpps on [HHS-NIH-NHLBI-CSB-2013-0086-DLM, February 5, 2013, TruSeq Custom Oligo Set]. Any information received as a result of this pre-solicitation / notice of intent will be considered solely for the purpose of determining whether to conduct any future competitive procurements. Responses to this notice shall contain sufficient documentation to establish the interested parties' bona-fide capabilities for fulfilling the requirement.

This notice of intent is not a request for competitive proposals. If you have any questions, please submit to the National Heart, Lung and Blood Institute, Office of Acquisition, COAC Services Branch, 6701 Rockledge Drive, Suite 6149, Bethesda, Maryland 20892-7902, Attention: Dorothy Maxwell. Response may be submitted electronically to [email protected]. Faxes will not be accepted.